leadf
logo-loader
viewAIM ImmunoTech Inc

Full interview: AIM ImmunoTech hopes to take the battle against COVID-19 to the front lines of China

AIM ImmunoTech (NYSE: AIM) CEO Thomas Equels joined Proactive New York's Christine Corrado on Skype with news the immuno-pharma company announced they have joined ChinaGoAbroad to bring their experimental drug Ampligen to China.

Equels telling Proactive how this drug will try to be a potential first line of defence against the dealy COVID-19 Virus. 

Quick facts: AIM ImmunoTech Inc

Price: 2.27 USD

NYSE:AIM
Market: NYSE
Market Cap: $90.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

ImagineAR and NFL Alumni sign 5 year sponsorship deal helping current and...

ImagineAR (CSE: IP-OTC: IPNFF) CEO Alen Paul Silverrstieen and NFL Alumni International Director Dean Dalton joined Steve Darling from Proactive to share the news that ImagineAR has signed a 5 year deal with NFL Alumni and it’s Academy Program. Silverrstieen talks about how this deal came...

6 minutes ago

2 min read